

ersonal use only



Annual General Meeting

May 2025

IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR)

WWW.IMRICOR.COM

Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems, Inc. (**Imricor**) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. None of Imricor, its officers, directors, employees and agents, nor any other person makes any representation or warranty as to the accuracy, completeness or reliability of the information contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (**US GAAP**) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements”. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding Imricor’s intent, belief or current expectations with respect to its business and operations, market conditions, results of operations and financial condition.

Imricor uses words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect Imricor’s current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond its control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon Imricor. There can be no assurance that future developments will be in accordance with Imricor’s expectations or that the effect of future developments on Imricor will be those anticipated. Actual results could differ materially from

those which we expect, depending on the outcome of various factors. Investors and others are cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic.

Imricor is under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

Imricor’s CHES Depositary Interests (**CDIs**) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.

Please submit questions at any time throughout the meeting



To ask a question select the 'Q&A' icon



Select the topic your question relates to.

Type your question into the chat box at the bottom of the screen and press 'Send'

Your question will be sent immediately for review

Broadcast Vote **Q & A** Documents

Your questions(s)

You may enter a question using the field below.

3 Adoption of Remuneration Report ▼

Enter your question here

24 character(s)

Send



Voting online at the virtual meeting

When the Chair declares the poll open, select the 'Vote' icon and the voting options will appear on your screen



Broadcast

Vote

Q & A

Documents

Items of Business

2A Re-elect Mr John Brown as a Director

FOR	AGAINST	ABSTAIN
-----	---------	---------

2B Re-elect Mr Peter Nolan as a Director

FOR	AGAINST	ABSTAIN
-----	---------	---------

To vote, select your voting direction. A tick will appear to confirm receipt of your vote

To change your vote, select 'Click here to change your vote' and press a different option to override.



Imricor's Board of Directors and CFO



Steve Wedan
Executive Chair,
President, & CEO



Mark Tibbles
Deputy Chair,
Non-Executive Director



Anita Messal
Non-Executive Director



Peter McGregor
Non-Executive Director



Jeffrey Leighton
Non-Executive Director



Jonathon Gut
CFO



ersonal use only

Chair's Address



imricor

"What may have taken several hours in the x-ray lab took less than an hour to perform using NorthStar in the iCMR."

Dr. Marco Götte - Amsterdam UMC, April 2024



Accomplishments in 2024 and up to today

- Expanded commercially into the Middle East
- Completed transition to EU's more stringent Medical Device Regulations
- Activated sites and building pipeline of new sites
- Commenced VISABL-AFL (supporting US FDA)
- Progressed US FDA approval processes across entire platform
- Commenced VISABL-VT (supporting expanded indications in EU)
- Strengthened balance sheet



Imricor Leadership Team

Management



Steve Wedan
President and Chief Executive Officer, and Board Chair



Jonathon Gut
Vice President of Finance and Chief Financial Officer



Gregg Stenzel
Chief Operating Officer



Jennifer Weisz
Vice President Regulatory & Quality



Nick Twohy
Vice President Marketing & Business Development



Dan Sunnarborg
Imricor B.V. Managing Director



Vic Fabano
Vice President Operations



Nick Corkill
Vice President Corporate Strategy



Kate Lindborg
Vice President Clinical Affairs



Greg Englehardt
Vice President Global Sales

Board of Directors



Steve Wedan
President and Chief Executive Officer, and Board Chair



Mark Tibbles
Deputy Chair and Lead Independent Director



Peter McGregor
Non-executive Director



Anita Messal
Non-executive Director



Jeffrey Leighton
Non-executive Director



ersonal use only

Business of the Meeting

imricor

Questions

Item 1 – Election of Class III Director – Mr Peter McGregor

To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That Mr Peter McGregor being a Director whose appointment as a Director expires at the conclusion of the Annual Meeting of the Company and, being eligible, offers himself for election, be elected as a Class III Director of the Company.”



Item 1 – Election of Class III Director – Mr Peter McGregor



Proxy and direct votes received in respect of this resolution:

For	Withheld	Non-Votes	Uncast
103,699,623	1,370,217	-	-
98.70%	1.30%		

ersonal use only



Item 2 – Election of Class III Director – Dr Jeffrey Leighton

To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That Dr Jeffrey Leighton being a Director whose appointment as a Director expires at the conclusion of the Annual Meeting of the Company and, being eligible, offers himself for election, be elected as a Class III Director of the Company.”



Item 2 – Election of Class III Director – Dr Jeffrey Leighton

Proxy and direct votes received in respect of this resolution:

For	Withheld	Non-Votes	Uncast
105,069,840	-	-	-
100%	-		



Item 3 – Approval of the 2019 Equity Incentive Plan and increase in reserved Shares

To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That, for the purposes of section 19.2 of the Plan (defined below), Exception 13 of ASX Listing Rule 7.2 and for all other purposes, the stockholders approve (i) the issue of equity securities under the Company’s 2019 Equity Incentive Plan (Plan) within three years from the date of passing this resolution as an exception to ASX Listing Rule 7.1; (ii) an increase in the aggregate number of shares of Class A common stock (Shares) that may be issued pursuant to awards under the Plan such that a total of 40,650,000 Shares will be reserved for issuance under the Plan, and (iii) consequential amendments to the Plan to reflect this increase.”

Note: A voting exclusion statement applies to this resolution (see the Explanatory Memorandum for details).



Item 3 – Approval of the 2019 Equity Incentive Plan and increase in reserved Shares

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
93,054,094	5,214,130	95,728	-	6,705,888
94.60%	5.30%	0.10%		



Item 4a – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company

To consider and, if thought fit, to pass the following resolutions as separate ordinary resolutions:

- (a) *“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to grant 455,893 options to purchase Shares (Options) as a long term incentive to the Chief Executive Officer of the Company, Mr Steve Wedan, under the Company’s 2019 Equity Incentive Plan (Plan), as described in, and on the terms and conditions set out in, the Explanatory Memorandum.”*

Note: A voting exclusion statement applies to this resolution (see the Explanatory Memorandum for details).



Item 4a – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
93,081,694	5,281,658	600	-	6,705,888
94.63%	5.37%	-		



Item 4b – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company

To consider and, if thought fit, to pass the following resolutions as separate ordinary resolutions:

- (b) *“That, subject to Item 3 being approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to grant 500,000 Options as a special one-off grant to the Chief Executive Officer of the Company, Mr Steve Wedan, under the Plan, as described in, and on the terms and conditions set out in, the Explanatory Memorandum.”*

Note: A voting exclusion statement applies to this resolution (see the Explanatory Memorandum for details).



Item 4b – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
71,570,518	26,732,834	60,600	-	6,705,888
72.76%	27.18%	0.06%		



Item 5 – Grant of Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company

To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That, subject to Item 1 being approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to grant a Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company, under the Plan, as described in, and on the terms and conditions set out in, the Explanatory Memorandum.”

Note: A voting exclusion statement applies to this resolution (see the Explanatory Memorandum for details).



Item 5 – Grant of Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
93,142,835	5,220,517	433,455	-	6,273,033
94.28%	5.28%	0.44%		



Item 6 – Grant of Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company

To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to grant a Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company, under the Plan, as described in, and on the terms and conditions set out in, the Explanatory Memorandum.”

Note: A voting exclusion statement applies to this resolution (see the Explanatory Memorandum for details)



Item 6 – Grant of Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
93,142,835	5,220,517	600	-	6,705,888
94.69%	5.31%	-		



Item 7 – Grant of Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company



To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to grant a Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company, under the Plan, as described in, and on the terms and conditions set out in, the Explanatory Memorandum.”

Note: A voting exclusion statement applies to this resolution (see the Explanatory Memorandum for details).



Item 7 – Grant of Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
93,088,694	5,274,658	600	-	6,705,888
94.64%	5.36%	-		



Item 8 – Ratification and approval of prior issue of CDIs under Placement

To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, the stockholders ratify and approve the prior allotment and issue of 49,645,391 CHESS Depositary Interests (CDIs) (equivalent to 49,645,391 shares of Class A Common Stock (Shares) at an issue price of A\$1.41 per CDI under a placement to professional and sophisticated investors (Placement), on the terms and conditions set out in, the Explanatory Memorandum.”

Note: A voting exclusion statement applies to this resolution (see the Explanatory Memorandum for details).



Item 8 – Ratification and approval of prior issue of CDIs under Placement

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
82,317,014	78,772	11,212,411	-	11,461,643
87.94%	0.08%	11.98%		



Item 9 – Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm

To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution:

“That the stockholders ratify and approve the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending 31 December 2025.”



Item 9 – Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm

Proxy and direct votes received in respect of this resolution:

For	Against	Abstain	Non-Votes	Uncast
105,057,128	4,581	8,131	-	-
99.99%	-	0.01%		



ersonal use only

Close of Meeting

imricor

Contact Information

Investors & Australian Media:

Simon Hinsley
NWR Communications
simon@nwrcommunications.com.au
+61 401 809 653

Investors:

Steve Wedan
Executive Chair, President & CEO
steve.wedan@imricor.com

Nick Corkill
Vice President, Corporate Strategy
Nick.corkill@imricor.com
+61 450 475 633

Rest of World Media:

Nick Twohy
Vice President, Marketing and Business Development
nick.twohy@imricor.com

imricor

FOLLOW US

